Two Sigma Advisers LP raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 1,493.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 694,814 shares of the medical device company’s stock after acquiring an additional 651,200 shares during the period. Two Sigma Advisers LP’s holdings in DexCom were worth $83,239,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of DXCM. Vanguard Group Inc lifted its stake in shares of DexCom by 11.5% in the 3rd quarter. Vanguard Group Inc now owns 7,942,861 shares of the medical device company’s stock worth $1,136,147,000 after purchasing an additional 816,247 shares during the period. Capital International Investors bought a new position in shares of DexCom in the 3rd quarter worth approximately $475,951,000. Geode Capital Management LLC lifted its stake in shares of DexCom by 17.2% in the 4th quarter. Geode Capital Management LLC now owns 1,042,131 shares of the medical device company’s stock worth $124,776,000 after purchasing an additional 152,781 shares during the period. Mackenzie Financial Corp lifted its stake in shares of DexCom by 13.7% in the 4th quarter. Mackenzie Financial Corp now owns 767,971 shares of the medical device company’s stock worth $92,003,000 after purchasing an additional 92,289 shares during the period. Finally, Two Sigma Investments LP lifted its stake in shares of DexCom by 596.5% in the 4th quarter. Two Sigma Investments LP now owns 731,059 shares of the medical device company’s stock worth $87,581,000 after purchasing an additional 626,098 shares during the period. Institutional investors and hedge funds own 97.55% of the company’s stock.
In related news, SVP Patrick Michael Murphy sold 400 shares of the firm’s stock in a transaction on Thursday, January 10th. The shares were sold at an average price of $138.75, for a total value of $55,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Donald Abbey sold 7,653 shares of the firm’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $142.79, for a total transaction of $1,092,771.87. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 102,181 shares of company stock valued at $14,473,795. Insiders own 1.80% of the company’s stock.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 21st. The medical device company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.38. DexCom had a negative net margin of 12.32% and a positive return on equity of 4.98%. The business had revenue of $338.00 million during the quarter, compared to analyst estimates of $331.60 million. During the same period last year, the firm posted $0.10 EPS. The company’s revenue was up 52.9% on a year-over-year basis. On average, sell-side analysts anticipate that DexCom, Inc. will post 0.46 earnings per share for the current year.
DXCM has been the topic of several recent research reports. Cowen increased their price objective on shares of DexCom from $150.00 to $175.00 and gave the stock an “outperform” rating in a research note on Friday, February 22nd. Morgan Stanley increased their price objective on shares of DexCom from $135.00 to $160.00 and gave the stock an “equal weight” rating in a research note on Monday, February 25th. BidaskClub cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday, November 20th. Canaccord Genuity increased their price objective on shares of DexCom from $140.00 to $160.00 and gave the stock a “buy” rating in a research note on Friday, February 22nd. Finally, Piper Jaffray Companies increased their price objective on shares of DexCom to $165.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 9th. Six equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $149.53.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Week Herald and is the property of of Week Herald. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://weekherald.com/2019/03/19/dexcom-inc-dxcm-shares-bought-by-two-sigma-advisers-lp.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Story: What is a short straddle?
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.